Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Burkitt Lymphoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Glioma 1Glioblastoma 1Down Syndrome 1Astrocytoma 1

Interventions

Cyclophosphamide 4Vincristine 3Doxorubicin 3romidepsin 2fludarabine 2Rituximab 2Oxaliplatin 2Lenalidomide 2Etoposide 2Azacitidine 2Alemtuzumab 2siplizumab 1obatoclax 1liposomal doxorubicin 1gossypol acetic acid 1fludarabine phosphate 1cediranib 1cc-486 1Valproic Acid 1Taxes 1Sunitinib 1Spinal Puncture 1Sorafenib 1Receptors, Chimeric Antigen 1Razoxane 1Prednisone 1Prednisolone 1Polymerase Chain Reaction 1Paclitaxel 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, T-Cell, Peripheral × Spinal Puncture × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡